Human induced pluripotent stem cells (hiPSCs) can be used to generate various cell types in the human body. Hence, hiPSC-derived cardiomyocytes (hiPSC-CMs) represent a significant cell source for disease modeling, drug testing, and regenerative medicine. The immaturity of hiPSC-CMs in two-dimensional (2D) culture limit their applications. Cardiac tissue engineering provides a new promise for both basic and clinical research. Advanced bioengineered cardiac in vitro models can create contractile structures that serve as exquisite in vitro heart microtissues for drug testing and disease modeling, thereby promoting the identification of better treatments for cardiovascular disorders. In this review, we will introduce recent advances of bioengineering technologies to produce in vitro cardiac tissues derived from hiPSCs.
Keywords: 3D bioprinting; 3D models; CPVT; ECM; Layer-by-Layer; cardiac organoid; cardiac tissue engineering; cardiomyocytes; differentiation; disease modeling; drug development; drug screening; heart-on-a-chip; hiPSC-CMs; human induced pluripotent stem cell; iPSC; maturation.